The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: A model-based analysis for Spain

Cost‐effectiveness of influenza vaccination of people aged 50–64 years in Australia: results are inconclusive

“…This uncertainty is depicted in a Cochrane review, 9 which estimated a 63% vaccine efficacy on preventing hospitalisations with a wide confidence interval (RR=0.37; 95% CI=0.12-1.12) using only one study. This is also evident in other five cost-effectiveness studies, where assumed efficacy ranged from 37% to 74% (14)(15)(16)(17)(18). In our study we have used a vaccine efficacy of 56% whereas the Newall study used a higher efficacy of 74% (Table 4), which favours a lower ICER in that study.…”

“…The ILI incidence is the central parameter used as a proxy for influenza in many models; [15][16][17] however, it is non-specific and is measured inconsistently. The in international perspective very low value of ILI incidence, based on the BEACH data, is likely to be due to bias, and prompted us to adopt a more reasonable looking, but clearly not data based, ILI3 scenario.…”

“…The five influenza cost-effectiveness studies have used an efficacy range from 43% to 74%. [14][15][16][17][18] We have used a vaccine efficacy of 33%, while the Newall study used a higher efficacy of 74%, which favours a lower ICER. (Table 4).…”

“…13 Researchers in several countries have assessed the cost-effectiveness of reducing the age threshold for vaccination to 50 years compared to the existing age threshold of 65 years, and suggested such policy changes would be cost-effective. [14][15][16][17] A recent costeffectiveness study in Australia by Newall et al showed similar results, suggesting policy changes to lower the immunisation age threshold. 18 This paper looks into the cost-effectiveness of influenza immunisation for people aged 50 to 64 in Australia, compares the results to the Newall study, illustrating the prime importance of some of the assumptions made, and draws some general conclusions from the comparison.…”

Are age-based strategies effective in increasing influenza vaccination coverage?: The Spanish experience

“…3 Previous economic evaluations have found that lowering the age limit for influenza vaccination in Spain and other countries would be cost effective. 20,21 These economic studies became especially relevant with the recent financial crisis and subsequent cuts in public health care expenditure. Uptake of the human papilloma virus e IRR for AR which lowered the age limit to 60 y using those AR which maintained the prior age as a reference.…”